The bone marrow microenvironment (BME) of myelodysplastic syndromes (MDS) is very different from the BME of acute myeloid leukemia (AML), and both are different from the BME of bone marrow without mutations, according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. Investigators, led by Maher Albitar, extracted RNA from fresh bone marrow samples of 626 patients with AML, 564 patients with MDS, and more than 1400 patients whose bone marrow was without any mutations (considered normal). Subsequently, the RNA levels of 42 immune biomarkers were assessed using next-generation sequencing. The researchers used a ...
Advertisement
Middle meningeal artery embolization is a novel, minimally invasive strategy that may help manage subdural hematomas in AML.
Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes.
Dexpramipexole was shown to significantly lower eosinophil counts compared with placebo in patients with eosinophilic asthma.
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
The Oncology Brothers were live at ASCO 2023 to discuss findings from the TROPiCS-02 study.
ASCO 2023: The Oncology Brothers Discuss ADAURA Trial Findings of Osimertinib for EGFR-Mutated NSCLC
The Oncology Brothers discuss findings from the phase 3 ADAURA trial.DocWire Content Partners
Get insights for cardiologists from the CardioNerds.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan discusses medical advances with renowned experts.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Expert interviews with Dr. Payal Kohli
